PT  - JOURNAL ARTICLE
AU  - Gray, Glenda E
AU  - Collie, Shirley
AU  - Garrett, Nigel
AU  - Goga, Ameena
AU  - Champion, Jared
AU  - Zylstra, Matthew
AU  - Reddy, Tarylee
AU  - Yende, Nonhlanhla
AU  - Seocharan, Ishen
AU  - Takalani, Azwi
AU  - Sanne, Ian
AU  - Mayat, Fatima
AU  - Odhiambo, Jacky
AU  - Bamford, Lesley
AU  - Moultrie, Harry
AU  - Fairall, Lara
AU  - Bekker, Linda-Gail
AU  - ,
TI  - Vaccine effectiveness against hospital admission in South African health care workers who received a homologous booster of Ad26.COV2 during an Omicron COVID19 wave: Preliminary Results of the Sisonke 2 Study
AID  - 10.1101/2021.12.28.21268436
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.12.28.21268436
4099  - http://medrxiv.org/content/early/2021/12/29/2021.12.28.21268436.short
4100  - http://medrxiv.org/content/early/2021/12/29/2021.12.28.21268436.full
AB  - Following the results of the ENSEMBLE 2 study, which demonstrated improved vaccine efficacy of a two-dose regimen of Ad26.COV.2 vaccine given 2 months apart, we expanded the Sisonke study which had provided single dose Ad26.COV.2 vaccine to almost 500 000 health care workers (HCW) in South Africa to include a booster dose of the Ad26.COV.2. Sisonke 2 enrolled 227 310 HCW from the 8 November to the 17 December 2021. Enrolment commenced before the onset of the Omicron driven fourth wave in South Africa affording us an opportunity to evaluate early VE in preventing hospital admissions of a homologous boost of the Ad26.COV.2 vaccine given 6-9 months after the initial vaccination in HCW.We estimated vaccine effectiveness (VE) of the Ad26.COV2.S vaccine booster in 69 092 HCW as compared to unvaccinated individuals enrolled in the same managed care organization using a test negative design. We compared VE against COVID19 admission for omicron during the period 15 November to 20 December 2021. After adjusting for confounders, we observed that VE for hospitalisation increased over time since booster dose, from 63% (95%CI 31-81%); to 84% (95% CI 67-92%) and then 85% (95% CI: 54-95%), 0-13 days, 14-27 days, and 1-2 months post-boost.We provide the first evidence of the effectiveness of a homologous Ad26.COV.2 vaccine boost given 6-9 months after the initial single vaccination series during a period of omicron variant circulation. This data is important given the increased reliance on the Ad26.COV.2 vaccine in Africa.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT05148845 Funding StatementFunding was provided by the National Treasury of South Africa, the National Department of Health, Solidarity Response Fund NPC, The Michael & Susan Dell Foundation, The Elma Vaccines and Immunization Foundation Grant number 21 V0001, and the Bill & Melinda Gates Foundation grant number INV 030342. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Protocol was reviewed and approved by the South African Health and Products Regulatory Agency, and all health research ethics committees associated with Sisonke clinical research sites. Approvals and data sharing agreements enabled research team access to anonymized unvaccinated datasets post matching. A protocol safety team met each week to review all safety events, break-through infections and deaths. The Protocol Safety Committee provided independent oversight of the study. The trial was registered at South African National Clinical Trial Registry; clin.gov and the Pan African Clinical Trials Registry. I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors